6 Korean listed companies match this signal: filing on clinical trial plans or results (90 days). All are listed on KOSDAQ. Sorted by most news articles in the past 24 hours, the list starts with ImmuneOncia Therapeutics, Voronoi and SillaJen. 5 of them also carry a red flag such as losses or dilution; check the signals column.

Clinical trial filing 6

Company	Articles 24h	Latest quarter op. profit	Dividend yield	Signals
ImmuneOncia Therapeutics KOSDAQ	6	−₩4.3bn	–	Clinical trial filing 4 quarters of losses
Voronoi KOSDAQ	6	−₩29.3bn	–	Clinical trial filing 4 quarters of losses
SillaJen KOSDAQ	2	−₩6.2bn	–	Clinical trial filing 4 quarters of losses
MedPacto KOSDAQ	1	−₩3.6bn	–	Clinical trial filing 4 quarters of losses
Keeps Biopharma KOSDAQ	0	−₩2.4bn	–	Revenue +30% Clinical trial filing
QuadMedicine KOSDAQ	0	−₩2.4bn	–	Clinical trial filing Swung to loss

Signals are generated automatically from DART filings (quarterly results, ownership reports, major-event reports and filing titles) and news counts. Prices and trading flows are not included. Not investment advice.

What this list means

Filings on clinical trial approvals or results. The trial phase and whether primary endpoints were met are key, and company statements can differ from regulators' conclusions.

Lists are generated automatically from filings and are not investment advice.

Signal definitions

Earnings

TurnaroundLatest quarter swung to an operating profit from a loss a year earlier
Profit +50%Latest quarterly operating profit up more than 50% year on year
Revenue +30%Latest quarterly revenue up more than 30% year on year
Revenue & profit growthLatest quarterly revenue and operating profit both up more than 10% year on year
Op. margin 20%+Operating margin of 20% or more on quarterly revenue of at least ₩5bn

Shareholder returns

BuybackTreasury share purchase or buyback trust decided in the past 90 days
CancellationBuyback with repurchased shares to be cancelled (90 days)
High dividendReported dividend yield of 5% or more in the latest annual report
Dividend growerDividend per share raised three years in a row

Ownership

Insider buyingOfficers or major shareholders reported adding shares (30 days)
New 5% holderA new 5%+ ownership report filed in the past 30 days
Major holder addingA 5%+ shareholder reported raising its stake (30 days)
Stake purpose changeA 5% ownership report changed the holding purpose, e.g. to influence management (90 days)

News & events

News surgeCoverage over the past 24 hours at least 3x the usual level
Supply contractSingle sales or supply contract disclosed in the past 30 days
Asset dealDecision to acquire or dispose of tangible assets (90 days)
M&A / stake dealMerger, spin-off or acquisition/sale of shares in another company (90 days)
Control changeChange of largest shareholder, or a contract that would cause one (90 days)
Private placementThird-party allotment rights offering decided in the past 90 days
Bonus issueBonus share issue decided in the past 90 days
Split / consolidationStock split or reverse split decided in the past 180 days
Treasury share saleDecision to sell treasury shares (90 days)
Clinical trial filingFiling on clinical trial plans or results (90 days)

Caution

Dilution riskRights offering or CB/BW/EB issue decided in the past 90 days
Swung to lossLatest quarter swung to an operating loss from a profit a year earlier
4 quarters of lossesOperating loss in each of the last four quarters
Insider sellingOfficers or major shareholders reported cutting shares (30 days)
Dividend cutDividend per share lower than, or dropped from, the prior year
Capital reductionCapital reduction decided in the past 180 days
LitigationLawsuit filed or ruled on, disclosed in the past 180 days
Share pledgeA 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days
Delisting / halt riskDelisting grounds, rehabilitation, bankruptcy or rumor-related trading halt (180 days)